Literature DB >> 29735500

Anaphylactic shock perioperative to patent blue dye.

João Pedro Azevedo1, Marta Alves1, Carmelita Ribeiro1, Ana Todo Bom1.   

Abstract

Patent blue is one of the most used dyes for the identification of sentinel lymph nodes in breast cancer. This report describes a case of an anaphylactic shock reaction to patent blue dye in a patient with cross-reactivity to methylene blue. Therefore, after allergy confirmation, the operation was repeated avoiding blue dye and an alternative labelling technique with 99mTc albumin nanocolloids was used. © BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  anaesthesia; healthcare improvement and patient safety; immunology; intensive care; medical management

Mesh:

Substances:

Year:  2018        PMID: 29735500      PMCID: PMC5950693          DOI: 10.1136/bcr-2018-224330

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  11 in total

1.  Near-fatal anaphylaxis to patent blue V.

Authors:  S Wöhrl; M Focke; G Hinterhuber; G Stingl; M Binder
Journal:  Br J Dermatol       Date:  2004-05       Impact factor: 9.302

2.  Basophil activation test in the diagnosis of patent blue V anaphylaxis.

Authors:  Monica Boita; Sabrina Mietta; Luisa Bommarito; Giovanni Rolla
Journal:  Ann Allergy Asthma Immunol       Date:  2015-07       Impact factor: 6.347

3.  Allergy to Blue Dye.

Authors:  J Martín-Lázaro; R Núñez-Orjales; N Battikhi-Precedo; S López-Freire; F Carballada-González
Journal:  J Investig Allergol Clin Immunol       Date:  2016       Impact factor: 4.333

4.  Hypersensitivity reactions during anesthesia. Results from the ninth French survey (2005-2007).

Authors:  S W Dong; P M Mertes; N Petitpain; F Hasdenteufel; J M Malinovsky
Journal:  Minerva Anestesiol       Date:  2012-03-22       Impact factor: 3.051

5.  [Acute blue urticaria following subcutaneous injection of patent blue dye].

Authors:  A Hamelin; A Vial-Dupuy; B Lebrun-Vignes; C Francès; A Soria; S Barete
Journal:  Ann Dermatol Venereol       Date:  2015-09-11       Impact factor: 0.777

Review 6.  Anaphylaxis to isosulfan blue and cross-reactivity to patent blue V: case report and review of the nomenclature of vital blue dyes.

Authors:  Kathrin Scherer; Wolfgang Studer; Verena Figueiredo; Andreas J Bircher
Journal:  Ann Allergy Asthma Immunol       Date:  2006-03       Impact factor: 6.347

7.  Atypical anaphylactic reaction to Patent Blue during sentinel lymph node biopsy for breast cancer.

Authors:  Sophocles Lanitis; George Filippakis; Virinder Sidhu; Ragheed Al Mufti; Tak H Lee; Dimitri J Hadjiminas
Journal:  Ann R Coll Surg Engl       Date:  2008-05       Impact factor: 1.891

8.  Anaphylaxis to Patent Blue V. I. Clinical aspects.

Authors:  A S Hunting; A Nopp; S G O Johansson; F Andersen; V Wilhelmsen; A B Guttormsen
Journal:  Allergy       Date:  2009-09-30       Impact factor: 13.146

9.  Anaphylaxis to dyes during the perioperative period: reports of 14 clinical cases.

Authors:  Paul Michel Mertes; Jean Marc Malinovsky; Claudie Mouton-Faivre; Marie Caroline Bonnet-Boyer; Abdelhaouad Benhaijoub; François Lavaud; Jocelyne Valfrey; James O'Brien; Philippe Pirat; Laurent Lalourcey; Pascal Demoly
Journal:  J Allergy Clin Immunol       Date:  2008-06-12       Impact factor: 10.793

10.  Multi-centre retrospective analysis of anaphylaxis during general anaesthesia in the United Kingdom: aetiology and diagnostic performance of acute serum tryptase.

Authors:  M T Krishna; M York; T Chin; G Gnanakumaran; J Heslegrave; C Derbridge; A Huissoon; L Diwakar; E Eren; R J Crossman; N Khan; A P Williams
Journal:  Clin Exp Immunol       Date:  2014-11       Impact factor: 4.330

View more
  1 in total

1.  Case report: Atypical anaphylactic reaction to Patent Blue V dye during breast cancer surgery.

Authors:  Stanka Misir Šitum; Iva Korečić Zrinjščak; Maja Pečvarac; Andrea Šoštar; Ana Žaja; Tea Tot
Journal:  Front Oncol       Date:  2022-09-16       Impact factor: 5.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.